prGCD

Protalix BioTherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific

CARMIEL, Israel, Dec. 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), noted today that prGCD, the Company's proprietary recombinant form of Glucocerebrosidase (GCD), which is used as an enzyme replacement therapy for Gaucher disease, was named one of the Five Most Pro...

prGCD in Medical Technology

Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

First patient treated in trial of prGCD treatment of Gaucher Disease CARMIEL, Israel, Aug. 27 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate,...

Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD

Phase III clinical trial may commence shortly CARMIEL, Israel, April 18, 2007 /PRNewswire-FirstCall/ --- Protalix BioTherapeutics, Inc. today announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in t...

prGCD in Biological Technology

Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel

...ansion of the manufacturing facility, Yossi Maimon, the Company's Chief Financial Officer, said, "In light of the progress we have made to date in our prgcd program, we determined that we should commence the expansion of our current facility. Our expanded facility will provide us with the space and capacit...